ClinicalTrials.gg
BiologicalDrug

Raxibacumab clinical trials

studies test it
3
open now
0
in phase 3
2
first study started
2008

How each study uses raxibacumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
14 Dec 2012 · RAXIBACUMAB · BLA 125349 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Raxibacumab
3

Studies by the year they started

3 studies that test it; most in 2008 (2)

Studies that test raxibacumab, by start year
YearStudies
20082
20151

By phase

A phase 1/2 study counts in both.

Phase 2
1
Phase 3
2
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 0

Human Genome Sciences Inc. (2) · Emergent BioSolutions (1)

Studies

Open first, then newest update. How each study uses raxibacumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Codes

What other systems call raxibacumab · ClinicalTrials.gg INT005462

  • MeSH (NLM) C542124raxibacumabOne source NLM
  • UNII (FDA) 794PGL549SRAXIBACUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1366567One source FDA
  • Wikidata Q7297093raxibacumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152160RaxibacumabOne source FDA
  • DrugBank DB08902One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.